Paragon Care Limited · ASX:PGC
Paragon Care — Shareholder Meeting (November 2025)
31 slides from Paragon Care's shareholder meeting presentation, Nov 19, 2025
Slide 1: ASX Announcement: 2025 AGM Chair Address & Presentation
19 November 2025 ASX ANNOUNCEMENT 2025 ANNUAL GENERAL MEETING – CHAIR ADDRESS & PRESENTATION Paragon Care Limited (ASX: PGC) (“ParagonCare” or the “Company”) attaches in accordance with ASX Listing Rule 3.13.3, the address to be delivered by Chair, Peter Lacaze and slides to be presented at today’s
Slide 2: Chair's Address
CHAIR’S ADDRESS Good afternoon, Last year we were at the early stages of the merger of CH2, Oborne Health Supplies and ParagonCare. This year we are reporting on progress with the integration and starting to outline the future growth prospects for the Company. • Overall, the 2025 financial results w
Slide 3: Annual General Meeting
Annual General Meeting 19 November 2025 ParagonCare Limited - ASX PGC
Slide 4: Disclaimer
Disclaimer Summary information This Presentation contains summary information about ParagonCare, and its activities current as at 19/11/2025. The information in the Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or potential in
Slide 5: Acknowledgement of Country and Traditional Owners
Acknowledgement of Country and Traditional Owners ParagonCare acknowledges the Traditional Owners of the country in which our headquarters are located, in Australia. We recognise the continuing connection to lands, waters and communities and pay our respects to Aboriginal and Torres Strait Islander
Slide 6: Introduction: Board Members
Introduction: Board Members David Collins Carmen Riley Peter Lacaze John Walstab Peter Egglestone Managing Director Executive Director and Non-Executive Chairman Non-Executive Director Non-Executive Director Chief Executive Officer
Slide 7: Format of Meeting
Format of Meeting Chair Address Question & Voting Procedure Formal Business CEO Presentation General Questions
Slide 8: Peter Lacaze, Chairman: Chair Address
Peter Lacaze Chairman Chair Address
Slide 9: Question & Voting Procedure
Question & Voting Procedure Annual General Meeting 2025
Slide 10: Formal Business
Formal Business Annual General Meeting 2025
Slide 11: Agenda Item 1: Financial Statements and Reports
Agenda Item 1 Receipt and Consideration of Financial Statements and Reports To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and auditors for the financial year ended 30 June 2025. Further information Ernst & You
Slide 12: Adoption of Remuneration Report
Strategic Resolutionoverview 1 Adoption of Remuneration Report To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report (included in the Directors' Re
Slide 13: Resolution 2: Election of Peter Egglestone
Resolution 2 Election of Mr Peter Egglestone as a Director To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That Mr Peter Egglestone, having been appointed as a Director during the year, and vacating office in accordance with the Company’s Constitution, bein
Slide 14: Resolution 3: Re-election of Peter Lacaze
Resolution 3 Re-election of Mr Peter Lacaze as a Director To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That Mr Peter Lacaze, being a Director who retires by rotation pursuant to the Company’s Constitution and being eligible for re-election, be re-elected
Slide 15: Resolution 4: Adoption of Omnibus Equity Plan
Resolution 4 Adoption of Paragon Care Limited Omnibus Equity Plan To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That, under and for the purposes of Listing Rule 7.2 Exception 13(b), and for all other purposes, Shareholders approve the adoption of the Comp
Slide 16: Resolution 5: Performance Rights to Carmen Riley
Resolution 5 Issue of Performance Rights to Ms Carmen Riley To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That, for the purposes of the purpose of Listing Rule 10.14 and for all other purposes, Shareholders approve the grant of 3,018,108 Performance Right
Slide 17: Poll & Close of Formal Business
Poll & Close of Formal Business Annual General Meeting 2025 ParagonCare Limited - ASX PGC
Slide 18: Carmen Riley, CEO: CEO Presentation
Carmen Riley Chief Executive Officer CEO Presentation
Slide 19: Strategic Overview
Strategic Overview ParagonCare is a leading distribution network for all APAC providers of healthcare. We achieve this through a combination of customer focus, our extensive product range, knowledge-based solutions, and “best in class” logistics and technology. Our Strategy Our Vision Be a diversifie
Slide 20: ParagonCare APAC
ParagonCare ParagonCare APAC ParagonCare is a leading distribution network for all APAC providers of healthcare. ParagonCare now operates across 10 countries* in the APAC region and is continuing to pursue new markets. KOREA JAPAN ParagonCare offers distribution services in Wholesale, OEM and Medica
Slide 21: Channels to market - streamlined
Channels to market - streamlined Medical Contract Clinical Wholesale Technology Logistics Manufacturing • Pharmacy • OEM Capital • Pharmacy • Blood Reagents Markets • Medical Consumables • OEM Devices • Consumables • Contract Manufacturing • Complementary Medicine • Surgical Robotics • Devices • Re-
Slide 22: Year in review
Year in review Other Key highlights include: MedTech – new agencies signed Signed our first Contract Manufacturing agreement for the Mt Waverley site (and have since signed a 2nd contract) After the acquisition of Oborne by CH2 and then the merger of CH2 with Signed a new 4PL Medical contract with O
Slide 23: FY25 Key Highlights & Trading Update
FY25 Key Highlights & Trading Update
Slide 24: FY25 Results
FY25 Results FY25 Underlying $3.6+ billion $95.2 million* $31.2 million** Revenue EBITDA Net Profit After Tax FY25 Statutory $3.6+ billion $88.5 million $25.3 million** Revenue EBITDA Net Profit After Tax * FY25 Underlying EBITDA results reflect a full year of the consolidated contributions from CH2
Slide 25: Australia and New Zealand Overview
Australia and New Zealand Overview Revenue growth in line with expectations: Annual growth in Pharmacy of 11.6% within Australia continues to underpin topline performance within the region. Integration 90% completed, excluding manufacturing. Clinical Manufacturing fully operational and the first new
Slide 26: Asia Overview
Asia Overview Key highlights: FY25 revenue up 20%. We continue to look for new agency opportunities to broadened the product portfolio The proposed acquisition of Somnotec expected to expand range and geographic reach. Please refer to the announcement dated 28 October 2025. $m Sales HY25 HY24* Var $
Slide 27: FY26 Guidance
FY26 Guidance FY26 Underlying* $3.6 to 3.7 $97.5 to Debt 1.6x to 1.8x** billion $107.5 million EBITDA Revenue EBITDA Q1 Update ✓ Transition on track to complete our 3-2-1 Strategy by end of FY26 ✓ Retail Pharmacy Group debt recovery in negotiation ✓ New Brisbane site commissioned ✓ Investment into n
Slide 28: Somnotec Acquisition Overview
Somnotec Acquisition Overview Somnotec Group are a distributor of various leading edge medical devices and technology in Southeast Asia. Since the company’s incorporation in 2003, Somnotec have grown to serve diverse fields of medicine in addition to expanding respiratory and home care product lines
Slide 29: Key Focus FY26
Key focus FY26: Complete our 3-2-1 Strategy Organic Growth Opportunities Merger & Acquisition Operational efficiency
Slide 30: General Questions
General Questions Annual General Meeting 2025 ParagonCare Limited - ASX PGC
Slide 31: Thank you for joining us today
Thank you for joining us today